← Back to Search

Monoclonal Antibodies

LM-24C5 Dose Expansion for Solid Tumors

Phase 1 & 2
Recruiting
Research Sponsored by LaNova Medicines Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and no deterioration within 2 weeks prior to the first dose
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 96 weeks
Awards & highlights

Study Summary

This trial is being done to see if LM-24C5 is safe and well-tolerated in people with advanced solid tumors. The goal is to find the recommended dose for further testing.

Who is the study for?
This trial is for individuals with advanced solid tumors. Specific eligibility criteria are not provided, but typically participants must have a certain type and stage of cancer, meet health condition requirements, and may need to have tried other treatments first.Check my eligibility
What is being tested?
The study is testing LM-24C5's safety and how well patients can tolerate it. It aims to find the best dose that causes the fewest side effects in people with advanced solid tumors.See study design
What are the potential side effects?
Potential side effects of LM-24C5 are not listed, but common ones for cancer drugs include nausea, fatigue, risk of infection, hair loss, and reactions at the injection site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can perform daily activities without significant limitations.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~96 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 96 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage
Incidence of adverse events (AEs)
Incidence of dose-limiting toxicity (DLT)
+3 more
Secondary outcome measures
12-lead electrocardiogram (ECG) in RR, PR, QRS, QT, QTcF etc.
Blood Pressure in mmHg (Both Systolic and Diastolic blood pressure)
Changes of target lesions from baseline in Millimeter.
+23 more
Other outcome measures
Relationship between the biomarkers and the anti-tumor activity

Trial Design

2Treatment groups
Experimental Treatment
Group I: LM-24C5 Dose ExpansionExperimental Treatment1 Intervention
Group II: LM-24C5 Dose EscalationExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

LaNova Medicines LimitedLead Sponsor
8 Previous Clinical Trials
623 Total Patients Enrolled
Terry PangStudy DirectorLaNova

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

At present, how many distinct locations are simultaneously conducting this experimental investigation?

"Ocala Oncology in Ocala, Florida, Indiana University Melvan and Bren Simon Cancer Center in Indianapolis, Indiana, and Mary Crowley Cancer Research Center in Dallas, Texas are among the 6 additional locations where patients can enroll for this clinical trial."

Answered by AI

Are there currently any available slots for new participants in this medical trial?

"Based on the information provided by clinicaltrials.gov, this particular study is currently not seeking participants. The initial posting date was on December 1st, 2023, and the most recent update occurred on December 17th, 2023. However, it's worth noting that there are presently 2589 alternative studies actively recruiting and accepting candidates for participation."

Answered by AI

What is the primary objective of this investigation?

"The main focus of this clinical study is to assess the occurrence of serious adverse events (SAEs) within a 36-week period. In addition, secondary outcomes encompass overall survival (OS) measured in months during Phase 1, PK Parameter: Time of Maximum Observed Concentration (Tmax), evaluated in Phases 1 and 2, as well as various measurements from a 12-lead electrocardiogram (ECG), including RR interval, PR interval, QRS complex duration, QT interval, and QTcF correction factor during Phase 2."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Study of LM-24C5 For Advanced Solid Tumors
2023. "A Study of LM-24C5 For Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06187402.
All > Cincinnati > Indianapolis
~33 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top